Clinical Trial Update: tislelizUMaB in canceR Patients With molEcuLar residuaL Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tislelizumab in cancer patients with molecular residual disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Lung Cancer
• Pancreatic Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Cancer, Lung Cancer | Phase 3 | Status: RECRUITING